Red Flags

ALVO — Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retin

**THE CORE CONCERN**

The Beneish M-Score of 0.07 directly breaches the −1.78 manipulation threshold. On this negative scale, values closer to zero indicate higher statistical likelihood of earnings manipulation; the same model produced comparable readings for Enron in FY1997–1998. This reading coincides with an SGI component of 5.36, reflecting 436% year-on-year revenue growth, and an Altman Z-Score of −1.63 that places the company inside the distress zone (<1.81). Revenue expanded from $0.0B to $0.5B over the measured period at a 137% CAGR, while the accruals ratio remains near zero and cumulative net income has not yet diverged from operating cash flow.

**HISTORICAL PRECEDENT**

The combination of an M-Score near zero and extreme sales growth mirrors the profile of certain specialty pharmaceutical companies that later restated revenues after aggressive channel loading or milestone-recognition practices. In those cases, rapid reported top-line expansion initially masked the absence of sustained end-customer demand, producing M-Score deterioration three to four years before cash-flow shortfalls became visible in subsequent filings.

**WHAT TO VERIFY**

Investigators should examine three items. First, the composition of the most recent revenue increase: what portion consists of product sales to independent distributors versus direct end-customer purchases, and whether any distribution agreements contain return or inventory repurchase clauses. Second, the timing and amount of any milestone or licensing revenue recognized in the quarters that drove the 436% growth figure, cross-checked against the underlying contract terms disclosed in the 10-K or 10-Q. Third, the cash operating cycle: the change in days-sales-in-receivables and days-inventory relative to the revenue ramp, to determine whether working-capital absorption is consistent with genuine demand or with inventory build at channel partners.

**COUNTERARGUMENTS**

Alvotech operates in a pre-profitability, high-growth phase typical of biosimilar developers. Revenue CAGR of 137% and the associated SGI of 5.36 are expected outcomes during commercial launch and capacity expansion rather than automatic indicators of manipulation. The near-zero accruals ratio and absence of any years in which positive net income coincided with negative operating cash flow reduce the classic earnings-quality divergence that accompanied many past accounting failures. The 2% short interest further suggests that the market has not yet priced in widespread skepticism about reported figures. These signals therefore warrant examination of revenue quality and cash runway, but they can also arise from legitimate investment-phase economics in the drug-manufacturing sector.

BHRB — Burke & Herbert Financial Services Corp.

Burke & Herbert Financial Services Corp. operates as the bank holding company for Burke & Herbert Bank & Trust Company that provides various community banking products and services in Virginia and Maryland. The company offers consumer and commercial deposit products, such as digital banking, demand, negotiable order of withdrawal (NOW), money market, and savings accounts; and certificates of deposit. It also provides loans comprising commercial real estate, single family residential, owner-occupied commercial real estate, commercial and industrial, residential mortgage, and consumer non-real estate and other loans, as well as acquisition, construction, and development loans. In addition, it offers cash management services; online and mobile banking; and wealth and trust services. Further,

**THE CORE CONCERN**

The most direct quantitative signal is the Beneish M-Score of -1.41, which sits closer to zero than the -1.78 manipulation threshold. The same model output preceded Enron’s 2001 collapse by three years. The score is driven primarily by the sales growth index (SGI) of 2.35, corresponding to 135 percent year-over-year revenue expansion. Revenue moved from a stable $0.1 billion base to $0.3 billion, producing a three-year CAGR of 31.4 percent. For a regional bank, this magnitude of top-line growth is uncommon and mechanically elevates several Beneish inputs even in the absence of discretionary accruals. The Altman Z-Score of 1.39 falls inside the distress zone, yet the metric was calibrated on manufacturing firms and carries limited weight for depository institutions whose capital structure and regulatory ratios differ materially. Accruals scaled by assets register 0.000, and there is no cumulative divergence between net income and operating cash flow across the measured periods.

**HISTORICAL PRECEDENT**

The M-Score pattern most closely tracks the 1997–1998 Enron profile, where rapid reported revenue growth combined with an M-Score breach preceded later disclosure of aggressive contract accounting and special-purpose entities. In that case, the model flagged statistical likelihood of manipulation well before cash-flow shortfalls became visible. No identical banking precedent matches the current data exactly, but the combination of outsized SGI and an M-Score inside the manipulation band has historically warranted examination of revenue recognition timing and allowance adequacy.

**WHAT TO VERIFY**

Three items merit direct inspection in the 10-K or 10-Q. First, the composition of the recent revenue increase: quantify the portion attributable to organic loan origination versus acquisition accounting or purchase-accounting accretion. Second, the methodology and key assumptions behind the allowance for credit losses, specifically any changes in loss-given-default or economic forecast inputs that could compress provisions relative to loan growth. Third, the reconciliation of net interest income to cash interest received, including the treatment of deferred fees and costs on newly originated or acquired portfolios.

**COUNTERARGUMENTS**

Rapid revenue expansion itself generates elevated SGI and can push the composite M-Score closer to zero without requiring earnings manipulation; high-growth companies routinely produce this statistical profile. The company reports zero instances of positive net income paired with negative operating cash flow and zero cumulative NI–OCF divergence, which is inconsistent with classic accrual-based overstatement. Short interest remains modest at 3.4 percent of float. Because the firm operates in financial services rather than manufacturing, the Altman Z-Score’s distress classification is expected to overstate risk. These factors indicate that the forensic ratios may be registering growth dynamics rather than accounting distortion, and further analysis should focus on the sustainability and quality of the expanded loan book rather than presuming manipulation.